Skip to main content
. 2022 Apr 25;9:853217. doi: 10.3389/fcvm.2022.853217

Table 1.

Comparisons of demographics between survivors and non-survivors.

Variables Total (n = 13,279) Survivors (n = 12,006) Non-Survivors (n = 1,273) P -Value
Demographics and characteristics
Age, years 67.3 ± 14.3 66.6 ± 14.2 74.1 ± 13.7 <0.001
Male, % 8,339 (62.8) 7,652 (63.7) 687 (54.0) <0.001
Weight, kg 82.2 ± 19.6 82.7 ± 19.5 77.5 ± 20.7 <0.001
Caucasians, % 9,306 (70.1) 8,483 (70.7) 823 (64.7) 0.001
CCU, % 5,673 (42.7) 4,800 (40.0) 873 (68.6) <0.001
CSRU, % 7,606 (56.1) 7,206 (60.0) 400 (31.4) <0.001
SAPS 18.4 ± 5.2 18.0 ± 4.9 22.2 ± 6.1 <0.001
SOFA 4.2 ± 2.8 3.9 ± 2.6 6.3 ± 3.8 <0.001
Interventions
Mechanical ventilation use (1st 24 h) 7,914 (59.6) 7,187 (59.9) 727 (57.1) 0.057
Vasopressor use (1st 24 h) 7,490 (56.4) 6,682 (55.7) 808 (63.5) <0.001
Vital signs
Temperature, °C 36.8 ± 0.6 36.8 ± 0.5 36.6 ± 0.9 <0.001
Respiratory rate, bpm 18.0 ± 3.5 17.8 ± 3.3 20.0 ± 4.5 <0.001
MAP, mmHg 75.9 ± 9.2 76.2 ± 8.8 73.3 ± 11.5 <0.001
Heart rate, bpm 82.7 ± 13.8 82.2 ± 13.3 87.0 ± 17.1 <0.001
SpO2, % 91.8 ± 7.3 92.2 ± 6.4 87.7 ± 12.6 <0.001
Comorbidities
CHF, % 4,067 (30.6) 3,479 (29.0) 588 (46.2) <0.001
  CHF–acute, % 2,283 (17.2) 1,893 (15.8) 390 (30.6) <0.001
  CHF–systolic, % 2,546 (19.2) 2,108 (17.6) 438 (34.4) <0.001
HTN, % 7,059 (53.2) 6,590 (54.9) 469 (36.8) <0.001
CAD, % 7,970 (60.0) 7,449 (62.0) 521 (40.9) <0.001
  AMI, % 1,650 (12.4) 1,408 (11.7) 242 (19.0) <0.001
VA, % 1,185 (8.9) 965 (8.0) 220 (17.3) <0.001
Diabetes, % 3,968 (29.9) 3,914 (30.1) 354 (27.8) 0.089
COPD, % 164 (1.2) 128 (1.1) 36 (2.8) <0.001
Pneumonia, % 1,516 (11.4) 1,212 (10.1) 304 (23.9) <0.001
Sepsis, % 321 (2.4) 150 (1.2) 171 (13.4) <0.001
AKI, % 1,597 (12.0) 1,235 (10.3) 362 (28.4) <0.001
CKD, % 869 (6.5) 740 (6.2) 129 (10.1) <0.001
Liver disease, % 381 (2.9) 308 (2.6) 73 (5.7) <0.001
  Hepatitis, % 298 (2.2) 259 (2.2) 39 (3.1) 0.038
  MELD score 15.8 ± 9.0 13.5 ± 7.0 24.2 ± 10.4 <0.001
Stroke, % 398 (3.0) 296 (2.5) 102 (8.0) <0.001
Cancer, % 1,898 (14.3) 1,663 (13.9) 235 (18.5) <0.001
Laboratory tests
WBC, × 109/L 12.2 ± 5.8 12.0 ± 5.4 14.2 ± 8.3 <0.001
Platelet, × 109/L 198.8 ± 86.9 199.7 ± 84.6 218.6 ± 104.0 <0.001
Hemoglobin, g/dL 10.9 ± 2.5 10.9 ± 2.5 11.4 ± 3.1 <0.001
Sodium, mmol/L 137.4 ± 3.8 137.4 ± 3.6 137.7 ± 5.6 0.096
Potassium, mmol/L 4.4 ± 1.0 4.4 ± 1.0 4.6 ± 1.5 <0.001
Chlorine, mmol/L 105.7 ± 5.3 105.9 ± 5.1 104.0 ± 6.9 <0.001
Glucose, mmol/L 7.6 ± 2.2 7.5 ± 1.9 8.8 ± 3.6 <0.001
Creatinine, mg/dL 1.2 ± 1.1 1.1 ± 1.1 1.7 ± 1.3 <0.001
Urea nitrogen, mg/dL 22.2 ± 16.3 20.9 ± 14.7 34.8 ± 23.5 <0.001
Urine output (1st 24 h), mL/kg/h 1.08 ± 0.72 1.10 ± 0.69 0.91 ± 0.95 <0.001
<0.5, % 2,566 (19.3) 1,996 (16.6) 570 (44.8)
0.5–1.0, % 4,764 (35.9) 4,446 (37.0) 318 (25.0)
1.0-1.5, % 3,114 (23.5) 2,972 (24.8) 142 (11.2)
1.5-2.0, % 1,485 (11.2) 1,416 (11.8) 69 (5.4)
≥2.0, % 1,350 (10.2) 1,176 (9.8) 174 (13.7)
Diuretic, % 9,358 (70.5) 8,640 (72.0) 718 (56.4) <0.001

CCU, coronary care unit; CSRU, cardiac surgery recovery unit; SAPS, simplified acute physiology score; SOFA, sequential organ failure assessment; MAP, mean aortic pressure; SpO2, oxyhemoglobin saturation; CHF, congestive heart failure; HTN, hypertension; CAD, coronary artery disease; AMI, acute myocardial infarction; VA, ventricular arrhythmia; COPD, chronic obstructive pulmonary disease; AKI, acute kidney injury; CKD, chronic kidney disease; MELD, model for end-stage liver disease; WBC, white blood cell.